1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613–620.
2. Hooper R, Burney P, Vollmer WM et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39: 1343–1353.
3. Koblížek V, Chlumský J, Zindr V et al. Chronic obstructive pulmonary disease in the light of new guidelines – brief summary of phenotypically oriented guidelines for nonpulmonary physicians. Vnitř Lék 2013; 59: 505–514.
4. Miravitlles M, Soler‑Cataluña JJ, Calle M et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012; 48: 247–257.
5. Hronek M, Kovarik M, Aimova P et al. Skinfold anthropometry-the accurate method for fat free mass measurement in COPD. COPD 2013; 10: 597–603.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. 2013 Feb [cited 2013 Nov 2]. Available from: http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
7. Lamprecht B, McBurnie MA, Vollmer WM et al. COPD in never smokers: results from the population‑based burden of obstructive lung disease study. Chest 2011; 139: 752–763.
8. Malý M, Zvolský M, Rozborilová E et al. Respiratory Mortality in Czech and Slovak Republics in the year 2011. Stud Pneumol Phtiseol 2013; 73: 128–132.
9. Vondra V Úmrtnost na CHOPN v letech 1996–2005 se zdvojnásobila. Stud Pneumol Phtiseol 2007; 67: 75.
10. Institute of Medical Information Services. Tuberculosis and respiratory diseases 2011. 2012 Nov [cited 2013 Nov 2] Available from: http://www.uzis.cz/katalog/zdravotnicka‑statistika/tuberkuloza‑respiracni‑nemoci.
11. Hooper R, Burney P, Vollmer WM et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39: 1343–1353.
12. Bryant J, McDonald V, Boyes A et al. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res 2013; 14: 109.
13. Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. Ann Intern Med 2011; 155: 179–191.
14. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (updated) Clinical guidelines CG101. 2013 Mar [cited 2013 Nov 2]. Available from: http://www.nice.org.uk/CG101.
15. Celli BR. Update on the management of COPD. Chest 2008; 133: 1451–1462.
16. Czech Pneumological and Phthisiological Society. Guidelines for indication of home long term oxygen therapy 2013. 2013 Apr [cited 2013 Nov 2]. Available from: http://www. pneumologie.cz/odborne/doc/Standard%20 DDOT‑ %20final.pdf.
17. O'Donnell DE, Aaron S, Bourbeau J et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J 2007; 14: (Suppl B): 5B–32B.
18. Lange P, Marott JL, Vestbo J et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975–981.
19. Celli BR, Cote CG, Marin JM et al. The body‑mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012.
20. Anthoniesen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5‑year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–239.
21. Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010; 8: 84.
22. Troosters T, Molen T, Polkey M et al. Improving physical activity in COPD: towards a new paradigm. Respir Res 2013; 14: 115.
23. Decramer M, Celli BR, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT) a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
24. Mahler DA, D’Urzo A, Bateman ED et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilatation compared with tiotropium alone: a randomised, double‑blind comparison. Thorax 2012; 67: 781–788.
25. Tashkin DP, Fabbri LM Long‑acting beta‑agonist in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149.
26. Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‑blind, parallel‑group study. Lancet Respir Med 2013; 1: 199–209.
27. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbation of COPD. N Engl J Med 2011; 364: 1093–1103.
28. Calverley PM, Anderson JA, Celli BR et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
29. Miravitlles M, Calle M, Soler‑Cataluña JJ. Clinical phenotypes of COPD. Identification, definition and implications for quidelines. Arch Broncopneumol 2012; 48: 86–98.
30. Kerstjens H, Engel M, Dahl R et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198–1207.
31. Wells JM, Dransfield MT. Pathophysiology and clinical implication of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis 2013; 8: 509–521.
32. Beeh K, Glaab T, Stowasser S et al. Characterization of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res 2013; 14: 116.
33. Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 625–626.
34. Izquierdo‑Alonso JL, Rodriguez‑Gonzálezmoro JM, de Lucas‑Ramos P et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013; 107: 724–731.
35. Nava S, Sturani C, Hartl S et al. End‑of‑life decision – making in respiratory intermediate care units: a European survey. ERS TASK FORCE. Eur Respir J 2007; 30: 156–164.
36. Lanken PN, Terry PB, DeLisser HM et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177: 912–927.
37. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on the rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332–338.
38. Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‑controlled TORCH study. Respir Res 2009; 10: 59.
39. Laube BL, Janssens HM, Jongh FH et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308–1331.
40. O’Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–840.
41. Decramer ML Chapman KR, Dahl R et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524–533.
42. Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817.
43. Kesten S, Casaburi R, Kukafka D et al. Improvement in self‑reported exercise participation with combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008; 3: 127–136.
44. Singh S, Loke YK, Enright PL et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta‑analysis of randomised controlled trials. BMJ 2011; 342: d3215.
45. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium the FDA’s conclusions. N Engl J Med 2010; 363: 1097–1099.
46. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Tiotropium Respimat Pharmacokinetic Study in COPD[cited 2013 Nov 4] Available from: http://www.clinicaltrials.gov/ct2/show/NCT01222533.
47. Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491–1501.
48. Matejovska-Kubesova H, Weber P, Meluzinova H et al. Senioři a kardiovaskulární medikace. Vnitř Lék 2011; 57: 561–570.